ABSTRACT Strategies that would increase eggshell quality could be of considerable value to egg producers. This research demonstrated the effective use of fibroblast growth factor 23 (FGF-23) peptide vaccines to increase eggshell quality of Single Comb White Leghorn laying hens (from 69 to 72 wk of age). Hens, fed a standard diet (containing 900 IU/kg vitamin D 3 ), were intramuscularly injected (and boosted) with either a control vaccine (n = 14 hens) or one of 2 FGF-23 peptide vaccines (peptides NP1, GMNPPPYS; and NP7, YTSTERNSFH; n = 15 hens for each peptide). During peak antibody titer, eggs were collected for shell and internal quality analysis, hens were artificially inseminated, and the hatchability of fertilized eggs was determined. Laying hens vaccinated with either FGF-23 peptide NP1 or NP7 had increased (P < 0.05) plasma phosphate level (mmol/L; NP1 = 1.74, NP7 = 1.76, control = 1.47), egg specific gravity (NP1 = 1.083, NP7 = 1.083, control = 1.079), and eggshell strength (g of force; NP1 = 4002, NP7 = 4157, control = 3102) when compared to control vaccinated hens. FGF-23 peptide NP1 vaccinated hens also had increased eggshell thickness (mm, P < 0.001), shell weight (g, P = 0.032), and shell index (% of whole egg, P = 0.023) when compared to control vaccinated hens. FGF-23 peptide NP7 vaccinated hens tended to have decreased eggshell weight (P = 0.064) when compared to control vaccinated hens. Hatchability of fertilized eggs was not affected in incubations 1 and 3, but tended to be decreased (P = 0.097) by FGF-23 peptide NP1 vaccination in incubation 2. In conclusion, vaccines to FGF-23 peptides increased eggshell quality of laying hens with minimal adverse effects on egg internal quality. The effect of FGF-23 peptide vaccination on hatchability remains to be clarified.
INTRODUCTION
Economic loss due to egg breakage is a chronic problem to the poultry industry (James and Retzer, 1967) . Roland (1988) surveyed egg producers (representing 81 million laying hens) and estimated that 13 to 20% of the eggs laid were cracked or lost before reaching their final destination. Equipment advances have probably reduced egg loss to breakage since the report from Roland (1988) . Wolc et al. (2012) found that collected egg breakage in modern systems was as low as 0.63% of eggs laid from brown laying hens 18 to 35 wk of age. Egg loss reported by Wolc et al. (2012) did not account for egg loss during lay, which can range between 6.7 and 10.7% in battery and furnished cages, respectively (Mertens et al., 2006) . Also, as hens age, eggs become larger, and their susceptibility to breakage is greater than young hens studied by Wolc et al. (2012) . Bell and Weaver (2002) estimated that egg breakage in 60-week-old hens was as much as 3 times that of 20-to 29-week-old hens. Assuming a 1.3% average collectable egg loss and as much 6% loss at the point of lay, for a hen laying 300 eggs per yr, egg breakage could account for as much as a $0.91/yr/hen (assuming egg price at $0.50/doz). Eggshell quality (such as specific gravity, percent eggshell, and eggshell strength) is negatively correlated with egg breakage in commercial egg production and packing facilities (Strong, 1989) . A strategy that would increase eggshell quality could be of considerable value to egg producers, particularly in older laying hens, for which egg breakage is likely at its highest rate.
Calcium and vitamin D are 2 critical nutrients for assuring proper calcification of eggshell (Combs et al., 1979; Shen et al., 1981) . Calcium is always fed at levels that maximize eggshell quality. The use of dietary vitamin D for increasing eggshell quality is well established, and no insights have been seen for decades. The laying hen's ability to calcify eggshells was found to be positively correlated with circulating 1,25-dihydroxycholecalciferol (l,25(OH) 2 D 3 ) 882 concentrations as early as the 1980s (Nys et al., 1986; Soares et al., 1988) . Then, the optimal dietary level of vitamin D 3 for eggshell quality in laying hens was widely investigated (Shen et al., 1981; Mattila et al., 2004) . Vitamin D 3 metabolites, such as 25-hydroxycholecalciferol (25-OH-D 3 ) (Roland and Harms, 1976) , 1α-hydroxycholecalciferol (1α-OH-D 3 ) (Frost et al., 1990) , and l,25(OH) 2 D 3 (Newman and Leeson, 1999 ) also were applied into laying hen diets in an attempt to increase eggshell quality. While the results remain controversial, it is clear that a further increase in dietary vitamin D 3 and its metabolites, above the current industry level, will not yield additional improvement in eggshell quality (Roland and Harms, 1976; Hamilton, 1980; Frost et al., 1990; Keshavarz, 2003; Atencio et al., 2005; Ren et al., 2016d) .
Bone-derived fibroblast growth factor 23 (FGF-23) is a potent regulator of vitamin D metabolism. FGF-23 reduces the expression of 25-hydroxyvitamin D-1-hydroxylase (Cyp40) and elevates the expression of 24-hydroxylase (Cyp24) in the kidney, and thereby decreases circulating 1,25(OH) 2 D 3 (Shimada et al., 2004) . Blocking of the FGF-23 signaling pathway (i.e., gene ablation or antibody) resulted in marked increases in circulating l,25(OH) 2 D 3 levels in mice and humans (Yamazaki et al., 2008; Carpenter et al., 2014) . Previously, we showed that FGF-23 neutralization either via an FGF-23 peptide vaccine in hens or passive transfer of anti-FGF-23 peptide antibodies in progeny from vaccinated hens increased plasma l,25(OH) 2 D 3 levels (Ren et al., 2016a (Ren et al., , 2016c . During these studies, an observation was made that the eggs from hens injected with the FGF-23 peptide vaccine were more resistant to cracking than hens injected with a control vaccine. Studies were then conducted to determine if this observation could be supported by scientific data. The effect of FGF-23 peptide vaccination on hatchability also was determined.
MATERIALS AND METHODS
All procedures were approved by the College of Agricultural and Life Sciences Animal Care and Use Committee at the University of Wisconsin-Madison.
Hen vaccination
Commercial Single Comb White Leghorn laying hens (S&R Farms, Whitewater, WI) were individually housed in cages with raised wire floors and maintained under a 16-hour light: 8-hour dark lighting regimen with free access to feed (a standard diet as used in Ren et al., 2016c) and water. Two FGF-23 peptides (internally coded as NP1, GMNPPPYS; and NP7, YTSTERNSFH; synthesized by GeneScript, Piscatawy, NJ) were prepared as vaccines using a method previously described (Ren et al., 2016c) . Laying hens (24 wk old) were intramuscularly injected (breast and thigh muscle, see Trott et al. (2009) ) with either a control vaccine (prepared as described in Ren et al., 2016c , n = 14 hens), the peptide NP1 vaccine (n = 15 hens), or the peptide NP7 vaccine (n = 15 hens). Four booster injections (as described in Ren et al., 2016c) were conducted when hens were at 26, 28, 48 and 68 wk of age to maintain antibody levels. For each injection, the vaccine dose was 0.67 mg peptide per hen. Eggs collected one wk after the final injection were used to assess the presence of anti-FGF-23 peptide (NP1 or NP7) antibody. The indirect enzyme-linked immunosorbent assay (ELISA) for yolk antibody (IgY) detection was the same as we described in Ren et al. (2016c) . Hens were bled at 73 wk of age. Plasma phosphate and calcium levels were determined using commercial colorimetric assay kits (catalog number: phosphate, K410-500; calcium, k380-250) purchased from BioVision Inc. (Milpitas, CA).
Egg specific gravity
Eggs were collected for 20 consecutive d beginning when hens were at 69 wk of age and when antibody was at high titer (Ren et al., 2016c) . Specific gravity of the newly laid egg (measured immediately after daily egg collection) was done with sodium chloride and water solutions with molarity concentrations of 1.070, 1.074, 1.078, 1.082, 1.086, 1.090, 1.094, and 1.098 at volumes of 1,000 mL. The eggs were individually tested starting from lowest molarity to highest molarity, with the molarity in which the egg began floating recorded for the specific gravity measurement.
Egg quality
Eggs from specific gravity determination were immediately broken out for internal quality analysis. Egg weight (g), shell weight (g), yolk weight (g), albumen weight (g), dry matter content of the whole egg (%), dry matter content of the shell (%), dry matter content of the yolk (%), and dry matter content of the albumen (%) were determined. Shell index (shell weight/egg weight × 100%), yolk index (yolk weight/egg weight × 100%), albumen index (albumen weight/egg weight × 100%), the percent of shell dry matter in whole egg dry matter (%), the percent of yolk dry matter in whole egg dry matter (%), the percent of albumen dry matter in whole egg dry matter (%), and the yolk to albumen ratio (yolk weight: albumen weight, g: g) were measured and calculated.
Eggshell strength and thickness
For shell strength and thickness determination, eggs were collected for 5 consecutive d beginning when hens were 72 wk of age and when antibody was at high titer (Ren et al., 2016c) . Shell strength (the peak force value at shell breakage) was determined using a TA.HD , and an egg holder (diameter 32 mm, height 27 mm, plastic cap; eggs were positioned blunt end up). Three shell fragments (from blunt end, point end, and equator, respectively) from each egg were randomly chosen for thickness determination using a pressure-sensitive caliper (SPI, Garnden Grove, CA). Average thickness of the 3 fragments represented the shell thickness.
Hatchability
Either control or FGF-23 peptide NP1 vaccinated laying hens were artificially inseminated with pooled New Hampshire rooster semen once a wk for 2 consecutive wk beginning when hens were at 30 (incubation trial 1; control hens, 206 eggs in total; NP1 vaccinated hens, 238 eggs in total), 39 (incubation trial 2; control hens, 207 eggs in total; NP1 vaccinated hens, 212 eggs in total), and 52 (incubation trial 3; control hens, 242 eggs in total; NP1 vaccinated hens, 229 eggs in total) wk of age. Eggs were collected and incubated for 21 days. Eggs were candled on d 10 of incubation to determine fertility and early dead embryos. The incubator (d 1 to 18) was controlled at 37.5
• C with 58% RH. The hatcher (d 19 to 21) was controlled at 37.0
• C with 68% RH. The hatchability of fertilized eggs was calculated.
Statistical analysis
The average value from the group of eggs collected from an individual hen was used as the experimental unit. Plasma levels of phosphate and calcium and the eggshell and internal quality metrics were analyzed by one-way ANOVA (SPSS 23, IBM Corp., Chicago, IL). Differences between control and FGF-23 peptide (NP1 or NP7) vaccinated laying hens were determined using a 2-tailed Dunnett's test. A 2-tailed independent Student's t test was conducted to the compare the hatchability of fertilized eggs between control and FGF-23 peptide NP1 vaccinated hens. Data are shown as the mean±SE. The results were considered significantly different at P < 0.05, and a trend at P < 0.1.
RESULTS

Presence of anti-FGF-23 peptide antibody
As shown in Figure 1 , egg IgY from FGF-23 peptide (NP1 or NP7) vaccinated laying hens diluted as much as 1:8,000 showed specific binding to respective 
Plasma levels of phosphate and calcium
Either FGF-23 peptide NP1 (P < 0.001, Dunnett's test) or NP7 (P < 0.001, Dunnett's test) vaccinated hens had increased plasma phosphate level when compared to control vaccinated hens (Figure 2A ; NP1 = 1.74, NP7 = 1.76, control = 1.47; P < 0.001 for oneway ANOVA). No difference (P > 0.05) was observed on plasma calcium level ( Figure 2B ).
Eggshell quality
One-way ANOVA indicated that specific gravity (P = 0.026), shell strength (g of force, P < 0.001), shell thickness (mm, P < 0.001), shell weight (g, P = 0.035), and shell index (% of whole egg, P = 0.040) were significantly different between treatments. As presented in Figure 2 , Dunnett's test indicated that eggs from laying hens vaccinated with FGF-23 peptide NP1 had increased specific gravity (P = 0.046), shell strength (P < 0.001), shell thickness (P < 0.001), shell weight (P = 0.032), and shell index (P = 0.023) when compared to control hens. Laying hens vaccinated with FGF-23 peptide NP7 had increased specific gravity (P = 0.026) and shell strength (P < 0.001), and tended to have increased shell weight (P = 0.064) when compared to control hens (Dunnett's test).
Egg weight, egg internal quality, and hatchability of fertilized eggs
Egg weight and the egg internal quality measured were not affected by FGF-23 peptide (NP1 or NP7) vaccination (Table 1 , P > 0.05). Table 2 demonstrates that the hatchability of fertilized eggs was not affected Figure 2 . Plasma levels of phosphate and calcium and eggshell quality. Laying hens were vaccinated with either a control vaccine or FGF-23 peptide (NP1 or NP7) vaccines. Plasma samples and eggs were collected during peak antibody titer, and the (A) plasma phosphate level, (B) plasma calcium level, (C) egg specific gravity, (D) shell strength, (E) shell thickness, (F) shell weight, and (G) shell index were determined. Error bars denote SE of the mean. * , P < 0.05 compared with the control group (2-tailed Dunnett's test). 2 Three incubation trials were conducted when hens were at 30 (trial 1), 39 (trial 2), and 52 (trial 3) wk of age.
3 P-value from 2-tailed independent Student's t test.
in incubation trials 1 and 3 (P > 0.05), but tended to be decreased (P = 0.097) by FGF-23 peptide NP1 vaccination in incubation trial 2.
DISCUSSION
We have previously shown the effective use of synthetic peptide antibodies in targeting metabolic pathways of interest (Bobeck et al., 2015a (Bobeck et al., , 2015b Arendt et al., 2016; Sand et al., 2016) . Here, we demonstrate that FGF-23 peptide vaccines increased eggshell strength of laying hens by 29 to 34%, although the mechanism was not fully understood. In Bobeck et al. (2012) , Ren et al. (2016a) , Ren et al. (2016b) , and Ren et al. (2016c) , FGF-23 peptide vaccines increased circulating 1,25(OH) 2 D 3 levels of laying hens and chicks. Based on the reports that hens with higher plasma 1,25(OH) 2 D 3 levels had superior eggshell quality than those with lower plasma 1,25(OH) 2 D 3 levels (Nys et al., 1986; Soares et al., 1988) , it is possible that FGF-23 peptide vaccines increased eggshell strength by increasing plasma 1,25(OH) 2 D 3 levels of laying hens. In this study, the laying hens were fed 900 IU of vitamin D 3 per kg diet. According to Frost et al. (1990) , dietary supplementation of 1,25(OH) 2 D 3 in a diet containing more than 500 IU/kg vitamin D 3 would not affect eggshell quality. It is very interesting that, under a vitamin D 3 sufficient diet, eggshell quality could not be increased by dietary 1,25(OH) 2 D 3 supplementation but could be increased by increased endogenous 1,25(OH) 2 D 3 production.
Another possibility is that FGF-23 peptide vaccines increased eggshell strength by indirectly increasing the expression of ovocalyxins-32, a matrix protein concentrated in the eggshell that is critical for eggshell quality (Gautron et al., 2001; Takahashi et al., 2009; Takahashi et al., 2010) , in the shell gland. Hrabia et al. (2014) reported that administration of recombinant chicken growth hormone increased the gene expression of ovocalyxin-32 in the shell gland in laying hens. FGF-23 can indirectly decrease the secretion of growth hormone by decreasing the level of Klotho, which is a positive regulator of growth hormone secretion (Marsell et al., 2008; Quarles, 2012; Shahmoon et al., 2014) . To date, there is no report, to the best of our knowledge, with regards to the relationship between FGF-23 signaling and shell matrix protein secretion. Further experimentation is required to verify this mechanism.
Of particular note is that the blocking of the FGF-23 signaling pathway has been shown as effective in increasing body phosphate retention (Yamazaki et al., 2008; Ren et al., 2016a Ren et al., , 2016c . It is reported that eggshell quality is inversely related to dietary phosphorus levels above required levels (Miles et al., 1983; Boorman and Gunaratne, 2001) . In this study, the dietary non-phytate phosphorus level is 0.40%. Thus, a further increase of body phosphate retention (FGF-23 peptide NP1 and NP7 vaccines increased plasma phosphate by 18 and 19%, respectively) should have no benefit to eggshell quality. In this sense, the current results are unexpected. A possible explanation is that FGF-23 peptide vaccination increased eggshell quality by mechanisms other than phosphate metabolism. Strong (1989) reported that specific gravity and shell index were negatively correlated (P < 0.01) with egg breakage (with a correlation coefficient of -0.88 and -0.85, respectively) . In this study, FGF-23 peptide vaccines increased both specific gravity (NP1 and NP7) and shell index (NP1). Based on the data shown in Holder and Bradford (1979) , increasing the specific gravity from 1.079 (control hens in this study) to 1.083 (NP1 or NP7 vaccinated hens in this study) will decrease egg breakage of laying hens from 10.2 to 5.8%. Using this data, 13 additional eggs could be provided by a given hen (assuming 300 eggs/hen/yr) when FGF-23 peptide vaccines were injected, and effects are seen in younger and older hens. The current results suggest a potential commercial value of FGF-23 peptide vaccines.
The relationship between shell thickness and egg breakage is controversial. Bowman and Challender (1963) considered shell thickness as a reliable measurement to estimate egg breakage. Thompson et al. (1985) reported that shell thickness was significantly higher for the intact than for the cracked eggs. Others, such as Strong (1989) and Potts and Washburn (1974) , showed a lack of correlation between shell thickness and egg breakage. In this study, while FGF-23 peptide NP1 vaccine increased both shell thickness and strength, peptide NP7 vaccine increased shell strength with no effect on thickness. The current results suggest shell thickness is not necessarily a predictive variable for shell strength.
During this study, the laying performance was not influenced by FGF-23 peptide vaccination. Control hens had an average egg laying rate of 87% (ranged from 77 to 100%), similar to that of NP1 (average 88%, ranged from 77 to 100%) and NP7 (average 87%, ranged from 53 to 100%) vaccinated hens. The vaccination of FGF-23 peptides had no adverse effects on any measure of egg internal quality; hence, eggshell strength could be increased without adversely affecting internal or edible egg quality. Most important is that yolk and albumen dry matter were not adversely affected by the use of FGF-23 peptide vaccinations. Maintenance of dry matter is important to egg breaking operations, which want to maintain solids levels for egg drying.
In Ren et al. (2016c) , FGF-23 peptide NP1 vaccination decreased excreta phosphorus levels of laying hens, and revealed a potential to decrease laying hen dietary inorganic phosphate input. The current observations (increased eggshell quality could subsequently decrease egg breakage) suggest additional value of FGF-23 peptide vaccines in laying hens. Otherwise, we have previously showed that maternally derived anti-FGF-23 antibodies decreased the dietary non-phytate phosphorus requirement of progeny chicks (Bobeck et al., 2012; Ren et al., 2016a) . These observations suggest a potential value of FGF-23 peptide vaccination in broiler breeders. Since FGF-23 peptide vaccines increased eggshell strength, which would make it harder for the embryos to break eggshell at hatch, we further investigated the effect of FGF-23 peptide vaccines on hatchability of fertilized eggs. While significant difference was not observed, FGF-23 peptide NP1 vaccine tended to decrease (by 18%) the hatchability of fertilized eggs in incubation trial 2. It is possible that the egg numbers for determining hatchability are insufficient to demonstrate a statistical significance, because normally differences in hatchability require several thousand eggs set for each treatment. Future studies will need to clarify whether FGF-23 peptide vaccine adversely affects hatchability in broiler breeders.
The finding that FGF-23 peptide NP7 vaccine was effective in inducing antibodies that increased eggshell quality was important. NP1 has sequence homology to human FGF-23 (Ren et al., 2016c) . Anti-NP1 antibodies could possibly bind to human FGF-23 if the egg containing the antibody was consumed by humans (e.g., not denatured through cooking) and the hormone was present in the gastrointestinal tract lumen (FGF-23 has not been shown to be present in the gastrointestinal tract lumen or to have any biological role in the gastrointestinal tract lumen). The potential cross reactivity of FGF-23 peptide NP1 antibody to human FGF-23 could be viewed as a potential food safety issue. However, FGF-23 peptide NP7, which is much less homologous to the sequence in humans (chicken, YT-STERNSFH; human, YTATARNSYH;3 nonmatching amino acids), suggests that antibody to chicken FGF-23 (e.g., NP7) is less likely to cross react with human FGF-23.
In conclusion, FGF-23 peptide vaccines effectively increased eggshell quality with no adverse effects on egg internal quality. To the best of or knowledge, this is the first report on the use of a vaccine to increase eggshell quality of laying hens. The effect of FGF-23 peptide vaccination on hatchability remains to be investigated.
